Abstract
Over-expression of TROP2 (the trophoblast cell surface antigen 2) was reported to predict poor prognosis in various solid tumors in number of studies. However, the results remained not comprehensive. Therefore, we here carried out this meta-analysis of relevant studies published on this topic to quantitatively evaluate the clinicopathological significance of TROP2 in solid tumors. Relevant articles were identified through searching the PubMed, Web of Science and Embase database. The primary outcomes were overall survival (OS) and disease-free survival (DFS). In this meta-analysis, 16 studies involving 2,569 participants were included, and we drew the conclusion that TROP2 overexpression was significantly associated with poor OS (pooled HR = 1.896, 95% CI = 1.599–2.247, P < 0.001) and short DFS (pooled HR = 2.336, 95% CI = 1.596–3.419, P < 0.001). Furthermore, the subgroup analysis revealed that the associations between TROP2 overexpression and the outcome endpoints (OS or DFS) were significant in in patients with female genital system neoplasms, as well in gastrointestine neoplasms. In addition, subgroup analysis found no difference HR across populations of different descent.Taken together, TROP2 overexpression was associated with poor survival in human solid tumors. TROP2 may be a valuable prognosis predictive biomarker and a potential therapeutic target in human solid tumors.
Highlights
Trophoblast cell surface antigen 2 (TROP2), known as GA733-1 or EGP-1 or TACSTD2, was a 36-kDa transmembrane glycoprotein, which was originally defined on normal and malignant trophoblast cells[1,2,3]
16 published studies including 2,569 patients that met the inclusion norm were selected for the meta-analysis, which assessed the relevance between TROP2 expression and solid tumor prognosis
The results suggested that TROP2 overexpression was associated with poor overall survival (OS) of solid tumors (Fig. 2). 6 studies were included in the meta-analysis of disease-free survival (DFS)
Summary
Trophoblast cell surface antigen 2 (TROP2), known as GA733-1 or EGP-1 or TACSTD2, was a 36-kDa transmembrane glycoprotein, which was originally defined on normal and malignant trophoblast cells[1,2,3]. Many studies showed that increased TROP2 expression in tumor tissues was correlated with poor survival of patients with various cancer types. We performed this comprehensive meta-analysis aiming to clarify the prognostic value of TROP2 in solid tumors and to support that the protein may be a potential therapeutic oncotarget.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
